
Ardent Health shares remain a strong buy despite profit dips and margin pressures.
Ardent Health's stock is considered undervalued and a 'buy' despite recent declines in profitability. The company’s revenue is growing, with management forecasting $6.4 to $6.7 billion for the year, though EBITDA and cash flow are expected to be lowe...





